|
Volumn 51, Issue 31, 2015, Pages 6812-6815
|
Acid-labile boronate-bridged dextran-bortezomib conjugate with up-regulated hypoxic tumor suppression
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BORONIC ACID DERIVATIVE;
BORTEZOMIB;
DEXTRAN;
ANTINEOPLASTIC AGENT;
DRUG CARRIER;
ACIDITY;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
CANCER INHIBITION;
DRUG CONJUGATION;
DRUG DELIVERY SYSTEM;
ENDOSOME;
ESTERIFICATION;
GLUCOSE BLOOD LEVEL;
IN VITRO STUDY;
INFRARED SPECTROSCOPY;
INTERNALIZATION;
LIGHT SCATTERING;
MASS SPECTROMETRY;
PROTON NUCLEAR MAGNETIC RESONANCE;
SPECTROPHOTOMETRY;
TISSUE ENGINEERING;
TRANSMISSION ELECTRON MICROSCOPY;
TUMOR MICROENVIRONMENT;
UPREGULATION;
ANIMAL;
APOPTOSIS;
CELL HYPOXIA;
CHEMISTRY;
DRUG EFFECTS;
DRUG RELEASE;
HUMAN;
MOUSE;
PH;
SIGNAL TRANSDUCTION;
TUMOR CELL LINE;
ANIMALS;
ANTINEOPLASTIC AGENTS;
APOPTOSIS;
BORONIC ACIDS;
BORTEZOMIB;
CELL HYPOXIA;
CELL LINE, TUMOR;
DEXTRANS;
DRUG CARRIERS;
DRUG LIBERATION;
ESTERIFICATION;
HUMANS;
HYDROGEN-ION CONCENTRATION;
MICE;
SIGNAL TRANSDUCTION;
UP-REGULATION;
|
EID: 84926628928
PISSN: 13597345
EISSN: 1364548X
Source Type: Journal
DOI: 10.1039/c5cc01371b Document Type: Article |
Times cited : (59)
|
References (13)
|